<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00419</drugbank-id>
  <drugbank-id>APRD01118</drugbank-id>
  <name>Miglustat</name>
  <description>Miglustat, commonly marketed under the trade name Zavesca, is a drug used to treat Gaucher disease. It inhibits the enzyme glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids. It is only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Miglustat is now the first and only approved therapy for patients with Niemann-Pick disease type C (NP-C). It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea. Miglustat was first developed as an anti-HIV agent in the 1990s. However, clinical experience with miglustat showed that therapeutic levels of the drug could not be achieved in patients without a high incidence of adverse effect.</description>
  <cas-number>72599-27-0</cas-number>
  <unii>ADN3S497AZ</unii>
  <average-mass>219.278</average-mass>
  <monoisotopic-mass>219.147058165</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A621</ref-id>
        <pubmed-id>17720777</pubmed-id>
        <citation>van Giersbergen PL, Dingemanse J: Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol. 2007 Oct;47(10):1277-82. Epub 2007 Aug 24.</citation>
      </article>
      <article>
        <ref-id>A622</ref-id>
        <pubmed-id>16247743</pubmed-id>
        <citation>Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9.</citation>
      </article>
      <article>
        <ref-id>A623</ref-id>
        <pubmed-id>17689147</pubmed-id>
        <citation>Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE: Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol. 2007 Sep;6(9):765-72.</citation>
      </article>
      <article>
        <ref-id>A624</ref-id>
        <pubmed-id>12803929</pubmed-id>
        <citation>Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60.</citation>
      </article>
      <article>
        <ref-id>A625</ref-id>
        <pubmed-id>19956552</pubmed-id>
        <citation>Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18.</citation>
      </article>
      <article>
        <ref-id>A626</ref-id>
        <pubmed-id>14609352</pubmed-id>
        <citation>McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6.</citation>
      </article>
      <article>
        <ref-id>A33282</ref-id>
        <pubmed-id>14757169</pubmed-id>
        <citation>Andersson U, Reinkensmeier G, Butters TD, Dwek RA, Platt FM: Inhibition of glycogen breakdown by imino sugars in vitro and in vivo. Biochem Pharmacol. 2004 Feb 15;67(4):697-705.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of adult patients with mild to moderate type 1 (nonneuropathic) Gaucher's disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to constraints such as allergy, hypersensitivity, or poor venous access). Now approved in some countries for the treatment of progressive neurological symptoms in adult and pediatric patients with Niemann-Pick disease type C (NP-C). </indication>
  <pharmacodynamics>Miglustat, an N-alkylated imino sugar, is a synthetic analogue of D-glucose. Miglustat is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for catalyzing the formation of glucosylceramide (glucocerebroside). Glucosylceramide is a substrate for the endogenous glucocerebrosidase, an enzyme that is deficient in Gaucher's disease. The accumulation of glucosylceramide due to the absence of glucocerebrosidase results in the storage of this material in the lysosomes of tissue macrophages, leading to widespread pathology due to infiltration of lipid-engorged macrophages in the viscera, lymph nodes, and bone marrow. This results in secondary hematologic consequences including sever anemia and thrombocytopenia, in addition to the characteristic progressive hepatosplenomegaly, as well as skeletal complications including osteonecrosis and osteopenia with secondary pathological fractures.</pharmacodynamics>
  <mechanism-of-action>Miglustat functions as a competitive and reversible inhibitor of the enzyme glucosylceramide synthase, the initial enzyme in a series of reactions which results in the synthesis of most glycosphingolipids. The goal of treatment with miglustat is to reduce the rate of glycosphingolipid biosynthesis so that the amount of glycosphingolipid substrate is reduced to a level which allows the residual activity of the deficient glucocerebrosidase enzyme to be more effective (substrate reduction therapy), reducing the accumulation of glucocerebroside in macrophages. In vitro and in vivo studies have shown that miglustat can reduce the synthesis of glucosylceramide-based glycosphingolipids. In clinical trials, miglustat improved liver and spleen volume, as well as hemoglobin concentration and platelet count. Inhibition of glycosphingolipid synthesis has also shown to reduce intracellular lipid storage, improve fluid-phase endosomal uptake and normalize lipid transport in peripheral blood B lymphocytes of NP-C patients, which results in a decrease in the potentially neurotoxic accumulation of gnagliosides G&lt;sub&gt;M2&lt;/sub&gt; and G&lt;sub&gt;M3&lt;/sub&gt;, lactosylceramide and glucosylceramide, possibly preventing further neuronal damage. Other studies have also suggested that miglustat may indirectly modulate intracellular calcium homeostasis through its effects on glucosylceramide levels, and evidence has shown that an initiating factor in the pathogenesis of NP-C may be impaired calcium homeostasis related to sphingosine storage. Therefore, the effect that miglustat exerts on intracellular calcium levels may influence an important underlying pathogenic mechanism of NP-C.</mechanism-of-action>
  <toxicity>Miglustat has been administered at doses of up to 3000 mg/day (approximately 10 times the recommended starting dose administered to Gaucher patients) for up to six months in Human Immunodeficiency Virus (HIV)-positive patients. Adverse events observed in the HIV studies included granulocytopenia, dizziness, and paresthesia. Leukopenia and neutropenia have also been observed in a similar group of patients receiving 800 mg/day or above.</toxicity>
  <metabolism>There is no evidence that miglustat is metabolized in humans.</metabolism>
  <absorption>Mean oral bioavailability is 97%.</absorption>
  <half-life>The effective half-life of miglustat is approximately 6 to 7 hours.</half-life>
  <protein-binding>Miglustat does not bind to plasma proteins.</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as piperidines. These are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms.</description>
    <direct-parent>Piperidines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Piperidines</class>
    <subclass/>
    <alternative-parent>1,2-aminoalcohols</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Polyols</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <alternative-parent>Secondary alcohols</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1,2-aminoalcohol</substituent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic heteromonocyclic compound</substituent>
    <substituent>Amine</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Piperidine</substituent>
    <substituent>Polyol</substituent>
    <substituent>Primary alcohol</substituent>
    <substituent>Secondary alcohol</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000621</drugbank-id>
      <name>Miglustat hydrochloride</name>
      <unii/>
      <cas-number>210110-90-0</cas-number>
      <inchikey>QPAFAUYWVZMWPR-ZSOUGHPYSA-N</inchikey>
      <average-mass>255.74</average-mass>
      <monoisotopic-mass>255.1237359</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">BuDNJ</synonym>
    <synonym language="english" coder="">Butyldeoxynojirimycin</synonym>
    <synonym language="english" coder="inn/usan">Miglustat</synonym>
    <synonym language="latin" coder="inn">Miglustatum</synonym>
    <synonym language="english" coder="">N-(n-Butyl)deoxynojirimycin</synonym>
    <synonym language="english" coder="">n-Butyl deoxynojirimycin</synonym>
    <synonym language="english" coder="">N-butyl-1-deoxynojirimycin</synonym>
    <synonym language="english" coder="">N-Butylmoranoline</synonym>
    <synonym language="english" coder="">NB-DNJ</synonym>
  </synonyms>
  <products>
    <product>
      <name>Miglustat</name>
      <labeller>Amerigen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43975-310</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA208342</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miglustat</name>
      <labeller>CoTherix, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10148-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021348</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Miglustat</name>
      <labeller>Johnson Matthey Pharmaceuticals Services</labeller>
      <ndc-id/>
      <ndc-product-code>50137-4237</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-08-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder</dosage-form>
      <strength>1 kg/1kg</strength>
      <route/>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Sandoz Miglustat</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02456257</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zavesca</name>
      <labeller>Actelion</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000435</ema-product-code>
      <ema-ma-number>EU/1/02/238/001</ema-ma-number>
      <started-marketing-on>2002-11-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Zavesca</name>
      <labeller>Actelion Pharmaceuticals US, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>66215-201</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2003-07-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021348</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zavesca</name>
      <labeller>Janssen Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02250519</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-05-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>100 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Zavesca</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Miglustat</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Zavesca</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Miglustat</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Miglustat</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Zavesca</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Miglustat</name>
      <ingredients>Miglustat</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Actelion Pharmaceuticals Inc.</name>
      <url>http://www.actelion.com</url>
    </packager>
    <packager>
      <name>Pharmaceutical Development and Manufacturing Services Ltd.</name>
      <url>http://www.pdms-almac.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Actelion pharmaceuticals ltd</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Zavesca 100 mg capsule</description>
      <cost currency="USD">160.67</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Alkaloids</category>
      <mesh-id>D000470</mesh-id>
    </category>
    <category>
      <category>Anti-HIV Agents</category>
      <mesh-id>D019380</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Enzyme Inhibitors</category>
      <mesh-id>D004791</mesh-id>
    </category>
    <category>
      <category>Gaucher Disease</category>
      <mesh-id>D005776</mesh-id>
    </category>
    <category>
      <category>Glucosylceramide Synthase Inhibitor</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glucosylceramide Synthase Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Glycoside Hydrolase Inhibitors</category>
      <mesh-id>D065089</mesh-id>
    </category>
    <category>
      <category>Imines</category>
      <mesh-id>D007097</mesh-id>
    </category>
    <category>
      <category>Imino Pyranoses</category>
      <mesh-id>D050112</mesh-id>
    </category>
    <category>
      <category>Imino Sugars</category>
      <mesh-id>D050111</mesh-id>
    </category>
    <category>
      <category>Miscellaneous Therapeutic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Piperidines</category>
      <mesh-id>D010880</mesh-id>
    </category>
    <category>
      <category>Various Alimentary Tract and Metabolism Products</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Powder</form>
      <route/>
      <strength>1 kg/1kg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>100 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AX06">
      <level code="A16AX">Various alimentary tract and metabolism products</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>92:00.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2v3d</pdb-entry>
    <pdb-entry>5ief</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00419.pdf?1265922796</fda-label>
  <patents>
    <patent>
      <number>5525616</number>
      <country>United States</country>
      <approved>1996-06-11</approved>
      <expires>2013-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5472969</number>
      <country>United States</country>
      <approved>1995-12-05</approved>
      <expires>2013-05-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Take without regard to meals, but always at the same time and in the same way.</food-interaction>
  </food-interactions>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>-1.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>0.18</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>3.31e+02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-1.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>miglustat</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>219.278</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>219.147058165</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C10H21NO4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C10H21NO4/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12/h7-10,12-15H,2-6H2,1H3/t7-,8+,9-,10-/m1/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UQRORFVVSGFNRO-UTINFBMNSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>84.16</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>55.74</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>23.99</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>12.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>8.49</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Highly soluble in water (&gt;1000 mg/mL as a free base).</value>
      <source/>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>169-172 Â°C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>13313</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>50381</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>51634</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506350</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D05032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>46764</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>18355</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10140</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>NBV</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000609</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Miglustat</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1029</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/zavesca.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/miglustat.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000477</id>
      <name>Ceramide glucosyltransferase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A624</ref-id>
            <pubmed-id>12803929</pubmed-id>
            <citation>Moyses C: Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):955-60.</citation>
          </article>
          <article>
            <ref-id>A622</ref-id>
            <pubmed-id>16247743</pubmed-id>
            <citation>Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P: Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005 Nov;80(3):223-9.</citation>
          </article>
          <article>
            <ref-id>A4824</ref-id>
            <pubmed-id>17603755</pubmed-id>
            <citation>Chien YH, Lee NC, Tsai LK, Huang AC, Peng SF, Chen SJ, Hwu WL: Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J Inherit Metab Dis. 2007 Oct;30(5):826. Epub 2007 Jun 21.</citation>
          </article>
          <article>
            <ref-id>A4825</ref-id>
            <pubmed-id>17624027</pubmed-id>
            <citation>Treiber A, Morand O, Clozel M: The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat. Xenobiotica. 2007 Mar;37(3):298-314.</citation>
          </article>
          <article>
            <ref-id>A4826</ref-id>
            <pubmed-id>18728838</pubmed-id>
            <citation>Ficicioglu C: Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manag. 2008 Apr;4(2):425-31.</citation>
          </article>
          <article>
            <ref-id>A625</ref-id>
            <pubmed-id>19956552</pubmed-id>
            <citation>Wraith JE, Imrie J: New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat. Ther Clin Risk Manag. 2009;5:877-87. Epub 2009 Nov 18.</citation>
          </article>
          <article>
            <ref-id>A4827</ref-id>
            <pubmed-id>18221193</pubmed-id>
            <citation>Pastores GM: Miglustat: substrate reduction therapy for lysosomal storage disorders associated with primary central nervous system involvement. Recent Pat CNS Drug Discov. 2006 Jan;1(1):77-82.</citation>
          </article>
          <article>
            <ref-id>A626</ref-id>
            <pubmed-id>14609352</pubmed-id>
            <citation>McCormack PL, Goa KL: Miglustat. Drugs. 2003;63(22):2427-34; discussion 2435-6.</citation>
          </article>
          <article>
            <ref-id>A4828</ref-id>
            <pubmed-id>16627252</pubmed-id>
            <citation>Giraldo P, Latre P, Alfonso P, Acedo A, Alonso D, Barez A, Corrales A, Franco R, Roldan V, Serrano S, Pocovi M: Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease. Haematologica. 2006 May;91(5):703-6. Epub 2006 Apr 19.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q16739" source="Swiss-Prot">
        <name>Ceramide glucosyltransferase</name>
        <general-function>Ceramide glucosyltransferase activity</general-function>
        <specific-function>Catalyzes the first glycosylation step in glycosphingolipid biosynthesis, the transfer of glucose to ceramide. May also serve as a "flippase".</specific-function>
        <gene-name>UGCG</gene-name>
        <locus>9q31</locus>
        <cellular-location>Golgi apparatus membrane</cellular-location>
        <transmembrane-regions>11-32
196-215
288-304
310-328
349-369</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.86</theoretical-pi>
        <molecular-weight>44853.255</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:12524</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>UGCG</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D50840</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1325917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q16739</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CEGT_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.4.1.80</synonym>
          <synonym>GCS</synonym>
          <synonym>GLCT-1</synonym>
          <synonym>Glucosylceramide synthase</synonym>
          <synonym>UDP-glucose ceramide glucosyltransferase</synonym>
          <synonym>UDP-glucose:N-acylsphingosine D-glucosyltransferase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016105|Ceramide glucosyltransferase
MALLDLALEGMAVFGFVLFLVLWLMHFMAIIYTRLHLNKKATDKQPYSKLPGVSLLKPLK
GVDPNLINNLETFFELDYPKYEVLLCVQDHDDPAIDVCKKLLGKYPNVDARLFIGGKKVG
INPKINNLMPGYEVAKYDLIWICDSGIRVIPDTLTDMVNQMTEKVGLVHGLPYVADRQGF
AATLEQVYFGTSHPRYYISANVTGFKCVTGMSCLMRKDVLDQAGGLIAFAQYIAEDYFMA
KAIADRGWRFAMSTQVAMQNSGSYSISQFQSRMIRWTKLRINMLPATIICEPISECFVAS
LIIGWAAHHVFRWDIMVFFMCHCLAWFIFDYIQLRGVQGGTLCFSKLDYAVAWFIRESMT
IYIFLSALWDPTISWRTGRYRLRCGGTAEEILDV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016106|Ceramide glucosyltransferase (UGCG)
ATGGCGCTGCTGGACCTGGCCTTGGAGGGAATGGCCGTCTTCGGGTTCGTCCTCTTCTTG
GTGCTGTGGCTGATGCATTTCATGGCTATCATCTACACCCGATTACACCTCAACAAGAAG
GCAACTGACAAACAGCCTTATAGCAAGCTCCCAGGTGTCTCTCTTCTGAAACCACTGAAA
GGGGTAGATCCTAACTTAATCAACAACCTGGAAACATTCTTTGAATTGGATTATCCCAAA
TATGAAGTGCTCCTTTGTGTACAAGATCATGATGATCCAGCCATTGATGTATGTAAGAAG
CTTCTTGGAAAATATCCAAATGTTGATGCTAGATTGTTTATAGGTGGCAAAAAAGTTGGC
ATTAATCCTAAAATTAATAATTTAATGCCAGGATATGAAGTTGCAAAGTATGATCTTATA
TGGATTTGTGATAGTGGAATAAGAGTAATTCCAGATACGCTTACTGACATGGTGAATCAA
ATGACAGAAAAAGTAGGCTTGGTTCACGGGCTGCCTTACGTAGCAGACAGACAGGGCTTT
GCTGCCACCTTAGAGCAGGTATATTTTGGAACTTCACATCCAAGATACTATATCTCTGCC
AATGTAACTGGTTTCAAATGTGTGACAGGAATGTCTTGTTTAATGAGAAAAGATGTGTTG
GATCAAGCAGGAGGACTTATAGCTTTTGCTCAGTACATTGCCGAAGATTACTTTATGGCC
AAAGCGATAGCTGACCGAGGTTGGAGGTTTGCAATGTCCACTCAAGTTGCAATGCAAAAC
TCTGGCTCATATTCAATTTCTCAGTTTCAATCCAGAATGATCAGGTGGACCAAACTACGA
ATTAACATGCTTCCTGCTACAATAATTTGTGAGCCAATTTCAGAATGCTTTGTTGCCAGT
TTAATTATTGGATGGGCAGCCCACCATGTGTTCAGATGGGATATTATGGTATTTTTCATG
TGTCATTGCCTGGCATGGTTTATATTTGACTACATTCAACTCAGGGGTGTCCAGGGTGGC
ACACTGTGTTTTTCAAAACTTGATTATGCAGTCGCCTGGTTCATCCGCGAATCCATGACA
ATATACATTTTTTTGTCTGCATTATGGGACCCAACTATAAGCTGGAGAACTGGTCGCTAC
AGATTACGCTGTGGGGGTACAGCAGAGGAAATCCTAGATGTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF13506</identifier>
            <name>Glyco_transf_21</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>Golgi membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ceramide glucosyltransferase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucosylceramide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycosphingolipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycosphingolipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein targeting to mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sphingolipid metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>